[Development of HIV 1 antigenemia during treatment with azidothymidine (AZT): follow-up of 90 patients for a year].
VIH 1 antigenaemia has a significant value in the follow-up of patients treated with AZT. This study of 90 patients (55 ARC - 35 AIDS), each receiving AZT for more than a year, 200 mg every 4 hours, demonstrates the prognosis value of antigenaemia at Day 0, as well as its therapeutic indication value. However, at term and under this treatment, the significance of this virological data has to be reconsidered. Various kinetic patterns are described according to the clinical status and the CD4+ cells count.
Berlie
H C
HC
Service de Bactériologie-Virologie et Comité SIDA, Saint-Antoine, Hôpital Saint-Antoine, Paris.
Berlioux
J
J
Daguet
G L
GL
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy / Q000276:immunology*; D000328:Adult; D015496:CD4-Positive T-Lymphocytes / Q000032:analysis; D005260:Female; D005500:Follow-Up Studies; D015488:HIV Antigens / Q000032:analysis* / Q000276:immunology; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D013997:Time Factors; D015215:Zidovudine / Q000627:therapeutic use*
D015488:HIV Antigens; D015215:Zidovudine
Evolution de l'antigénémie VIH 1 lors du traitement par l'azidothymidine (AZT): suivi de 90 malades à un an.